GlassScriptPhysician profile
Naomi E Arenson
NPI 1033102546
$4,408.14
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $126 · 2021: $335 · 2022: $2,147 · 2023: $732 · 2024: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,994.90 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $463.09 | 2019-2023 | Vumerity, Tysabri |
| Alexion Pharmaceuticals, INC. | $385.00 | 2019-2024 | |
| Emd Serono, INC. | $377.54 | 2022-2023 | Mavenclad |
| Abbvie INC. | $304.35 | 2022-2024 | Botox, Ubrelvy, Qulipta |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $108.30 | 2022-2023 | |
| Sk Life Science, INC. | $85.59 | 2022-2023 | |
| Lundbeck LLC | $73.09 | 2022 | |
| Neurelis, INC. | $68.83 | 2022-2023 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $59.61 | 2020 | |
| Allergan, INC. | $53.42 | 2020-2021 | |
| Orthofix Medical, INC. | $49.41 | 2022-2023 | Spinal-Stim, Spinal-Stim |
| Neurocrine Biosciences, INC. | $42.51 | 2022-2023 | Ongentys, Ingrezza |
| Celgene Corporation | $33.46 | 2020-2023 | Zeposia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $32.54 | 2022 | |
| Jazz Pharmaceuticals INC. | $27.65 | 2022 | |
| Genentech USA, INC. | $23.98 | 2022 | |
| Eisai INC. | $22.64 | 2024 | |
| Amgen INC. | $19.09 | 2023 | Aimovig |
| Nevro Corp. | $16.89 | 2021 | |
| Pfizer INC. | $15.82 | 2023 | |
| Supernus Pharmaceuticals, INC. | $12.77 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naomi Arenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.